Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2906155 | 0.87 | HTR6 (0.59) | HTR6ALDH1A1HTTL3MBTL1TSHR | |
| SCHEMBL14538994 | 0.86 | HTT (0.56) | HTR6ALDH1A1GAAHTTKMT2A | |
| SCHEMBL4293928 | 0.83 | HTR6 (0.69) | HTR6ALDH1A1GAAHTTKMT2A | |
| SCHEMBL2905648 | 0.83 | HTR6 (0.72) | HTR6HTTKMT2APKMPAX8 | |
| SCHEMBL13297277 | 0.73 | HTR6 (0.68) | HTR6ALDH1A1GAAHTTKMT2A | |
| SCHEMBL2905492 | 0.73 | HTR6 (0.55) | HTR6ALDH1A1GAAHTTKMT2A | |
| SCHEMBL2906880 | 0.73 | HTR6 (1.00) | HTR6 | |
| SCHEMBL14538809 | 0.73 | HTR6 (0.47) | HTR6ALDH1A1KMT2ALMNAMAPT | |
| SCHEMBL1958787 | 0.73 | MLNR (0.65) | HTR6ALDH1A1GAAHTTKMT2A | |
| SCHEMBL2907927 | 0.73 | HTR6 (1.00) | HTR6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | claimed |
| EP-2202222-A2 | Indene derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-30 | — | — | EP | claimed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | claimed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | claimed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | claimed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| US-8217041-B2 | Indene derivatives, their preparation and use as medicaments | Laboratories del Sr. Esteve, S.A. (ES) | 2012-07-10 | — | — | US | disclosed |
| EP-2202222-A2 | Indene derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-06-30 | — | — | EP | disclosed |
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2009-06-25 | — | — | US | disclosed |
| EP-2020230-A1 | Combination of at least two 5-HT6-Ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2009-02-04 | — | — | EP | disclosed |
| WO-2007054257-A2 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264457-A1 | Combination of at least two 5HT6-Ligands | HTR6, HTR3B, HTR4 | HTR6 1/4885ALDH1A1 1409/4885GAA 1232/4885 |
| US-20090163547-A1 | INDENE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICAMENTS | HTR6, HTR5A, HTR1A | HTR6 1/4885ALDH1A1 1050/4885GAA 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.